1. AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep. www.allergan.com/News/Details/2020/01/abbvie-and-allergan-announce-agreements-to-divest
2. MedImmune out-licenses potential medicine for inflammatory diseases to Allergan. www.astrazeneca.com/investor-relations/stock-exchange-announcements/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html#
3. AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio. www.astrazeneca.com/media-centre/press-releases/2012/astrazeneca-and-amgen-announce-collaboration-02042012.html#
4. BioNTech to acquire Neon to strengthen global leadership position in T cell therapies. https://investors.biontech.de/news-releases/news-release-details/biontech-acquire-neon-strengthen-global-leadership-position-t
5. Axsome Therapeutics enters into exclusive license agreement with Pfizer Inc. for Pfizer's reboxetine clinical and nonclinical data and for new Phase 3 esreboxetine product candidate. https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-enters-exclusive-license-agreement-pfizer?field_nir_news_date_value[min]=